Home>REGULATORY

Harvoni, Sovaldi under Review for Risks of Hypertension, Cerebrovascular Disorder(Jun.13.2016)
The Pharmaceuticals and Medical Devices Agency (PMDA) said on June 10 that it is reviewing the risks of hypertension and cerebrovascular disorder for hepatitis C drugs Harvoni (ledipasvir + sofosbuvir) and Sovaldi (sofosbuvir), a move that is likely to result ...
(LOG IN FOR FULL STORY)
- Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR Apr.20
- MHLW Sees Solid Inquiry Numbers for Conditional Early Approval System: Official Apr.19
- Generic Industry Asks for Govt Support for Continuous Manufacturing to Boost Int’l Competitiveness: Public-Private Confab Apr.17
- No Company Supports New Price Maintenance Premium Scheme: FPMAJ Survey Apr.17
-
Pharma Leaders Air Grievances on Pricing Reform Package at New MHLW Confab
Apr.17